Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maarten J Postma

Showing results (41-50 of 485) with videos related to

Pageof 49
Sort By:
Advances in Therapy|December 30, 2020
Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect ComparisonZalmai Hakimi, Elena Santagostino, Maarten J Postma, et al.
Journal of Medical Economics|March 16, 2026
Cost per event avoided: adopt or avoid?P Petrou, Olga Pitsillidou, Constantinos Petrou, et al.
Frontiers in Medical Technology|January 20, 2022
Efficacy, Safety, and Economics of Innovative Medicines: The Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and PolicyTanja Fens, Eugène P van Puijenbroek, Maarten J Postma
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 25, 2022
Differences in Evidentiary Requirements Between European Medicines Agency and European Health Technology Assessment of Oncology Drugs-Can Alignment Be Enhanced?Sharon Wolters, Frank G A Jansman, Maarten J Postma
Expert Review of Pharmacoeconomics & Outcomes Research|February 23, 2018
Access to anti-cancer drugs in India: is there a need to revise reimbursement policies?Gertruud Haitsma, Himanshu Patel, Parthasarathi Gurumurthy, et al.
Vaccine|July 4, 2012
Cost-effectiveness of pertussis booster vaccination in the NetherlandsMark H Rozenbaum, Elisabetta De Cao, Maarten J Postma
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 14, 2024
Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the NetherlandsSimon van der Pol, Maarten J Postma, Cornelis Boersma
Expert Review of Vaccines|January 10, 2025
Controlling the COVID-19 pandemic through vaccination: a perspective from IndonesiaRano K Sinuraya, Auliya A Suwantika, Maarten J Postma
Pharmaceutical Statistics|May 12, 2015
An alternative parameterization of Bayesian logistic hierarchical models for mixed treatment comparisonsPetros Pechlivanoglou, Fentaw Abegaz, Maarten J Postma, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
The use of modeling in the economic evaluation of vaccinesJasper M Bos, Loek van Alphen, Maarten J Postma
Pageof 49

Showing results (41-50 of 485) with videos related to

Sort By:
Pageof 49
Advances in Therapy|December 30, 2020
Recombinant FVIIIFc Versus BAY 94-9027 for Treatment of Patients with Haemophilia A: Comparative Efficacy Using a Matching Adjusted Indirect ComparisonZalmai Hakimi, Elena Santagostino, Maarten J Postma, et al.
Journal of Medical Economics|March 16, 2026
Cost per event avoided: adopt or avoid?P Petrou, Olga Pitsillidou, Constantinos Petrou, et al.
Frontiers in Medical Technology|January 20, 2022
Efficacy, Safety, and Economics of Innovative Medicines: The Role of Multi-Criteria Decision Analysis and Managed Entry Agreements in Practice and PolicyTanja Fens, Eugène P van Puijenbroek, Maarten J Postma
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 25, 2022
Differences in Evidentiary Requirements Between European Medicines Agency and European Health Technology Assessment of Oncology Drugs-Can Alignment Be Enhanced?Sharon Wolters, Frank G A Jansman, Maarten J Postma
Expert Review of Pharmacoeconomics & Outcomes Research|February 23, 2018
Access to anti-cancer drugs in India: is there a need to revise reimbursement policies?Gertruud Haitsma, Himanshu Patel, Parthasarathi Gurumurthy, et al.
Vaccine|July 4, 2012
Cost-effectiveness of pertussis booster vaccination in the NetherlandsMark H Rozenbaum, Elisabetta De Cao, Maarten J Postma
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|March 14, 2024
Antivirals to prepare for surges in influenza cases: an economic evaluation of baloxavir marboxil for the NetherlandsSimon van der Pol, Maarten J Postma, Cornelis Boersma
Expert Review of Vaccines|January 10, 2025
Controlling the COVID-19 pandemic through vaccination: a perspective from IndonesiaRano K Sinuraya, Auliya A Suwantika, Maarten J Postma
Pharmaceutical Statistics|May 12, 2015
An alternative parameterization of Bayesian logistic hierarchical models for mixed treatment comparisonsPetros Pechlivanoglou, Fentaw Abegaz, Maarten J Postma, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 8, 2009
The use of modeling in the economic evaluation of vaccinesJasper M Bos, Loek van Alphen, Maarten J Postma
Pageof 49